| Literature DB >> 31302671 |
Darius Häusler1, Sebastian Torke1, Evelyn Peelen2, Thomas Bertsch3, Marija Djukic1,4, Roland Nau1,4, Catherine Larochelle2, Scott S Zamvil5, Wolfgang Brück1, Martin S Weber1,6.
Abstract
Poor vitamin D status is associated with a higher relapse rate and earlier disability in multiple sclerosis. Based on these associations, patients with multiple sclerosis are frequently supplemented with the vitamin D precursor cholecalciferol, although it is unclear whether this regimen is of therapeutic benefit. To model consequences of this common practice, mice were fed for more than 3 months with a low, medium or high dose of cholecalciferol, representative of vitamin D deficiency, modest and disproportionally high supplementation, respectively, in patients with multiple sclerosis. Compared to vitamin D-deprived mice, its moderate supplementation reduced the severity of subsequent experimental autoimmune encephalomyelitis, which was associated with an expansion of regulatory T cells. Direct exposure of murine or human T cells to vitamin D metabolites inhibited their activation. In contrast, mice with 25-(OH) vitamin D levels above 200 nmol/l developed fulminant experimental autoimmune encephalomyelitis with massive CNS infiltration of activated myeloid cells, Th1 and Th17 cells. When dissecting this unexpected outcome, we observed that high, but not medium dose vitamin D had caused mild hypercalcaemia, which rendered T cells more prone to pro-inflammatory activation. Exposing murine or human T cells to equivalent calcium concentrations in vitro enhanced its influx, triggering activation, upregulation of pro-inflammatory gene products and enhanced transmigration across a blood-brain barrier model. These findings suggest that vitamin D at moderate levels may exert a direct regulatory effect, while continuous high dose vitamin D treatment could trigger multiple sclerosis disease activity by raising mean levels of T-cell excitatory calcium.Entities:
Keywords: T cells; calcium; experimental autoimmune encephalomyelitis; multiple sclerosis; vitamin D
Mesh:
Substances:
Year: 2019 PMID: 31302671 PMCID: PMC6736324 DOI: 10.1093/brain/awz190
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501